Methylnaltrexone
- Generic Name
- Methylnaltrexone
- Brand Names
- Relistor
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26NO4
- CAS Number
- 916055-93-1
- Unique Ingredient Identifier
- 0RK7M7IABE
- Background
Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. It is also a weak CYP2D6 inhibitor. FDA approved in 2008.
- Indication
Treatment of opioids induced constipation in palliative patients that are inadequately responding to laxative therapy.
- Associated Conditions
- Opioid Induced Constipation (OIC)
Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients
- Conditions
- STEMIMorphineTicagrelorMethylnaltrexone
- Interventions
- Drug: Sodium Chloride 9mg/mL
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2018-04-09
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT02942550
- Locations
- 🇸🇪
Södersjukhuset (Stockholm South General Hospital), Stockholm, Sweden
🇸🇪Karolinska University Hospital, Stockholm, Sweden
Study of Methylnaltrexone in Opioid-Induced Constipation Patients
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 198
- Registration Number
- NCT02574819
- Locations
- 🇨🇳
Henan Provincial Cancer Hospital, Zhengzhou, Henan, China
🇨🇳The Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China
🇨🇳Xin Hua Hospital affiliated to Shanghai Jiao Tong University School of Medicine Chongming Branch, Shanghai, Shanghai, China
Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 30
- Registration Number
- NCT02403830
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
Methylnaltrexone for Opioid Induced Constipation
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 7
- Registration Number
- NCT01955213
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Netherlands
🇳🇱Hospice Demeter, De Bilt, Netherlands
🇳🇱Medical Center Alkmaar, Alkmaar, Netherlands
Methylnaltrexone Pharmacokinetics in Neurointensive Care Patients
- Conditions
- Opioid Use, Unspecified With Other Opioid-induced Disorder
- Interventions
- First Posted Date
- 2013-06-28
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 9
- Registration Number
- NCT01889290
- Locations
- 🇨🇭
Neurointensive Care Unit, Zurich, Switzerland
Methylnaltrexone Use for Opioid-induced Postoperative Constipation
- Conditions
- Constipation
- Interventions
- Drug: Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax
- First Posted Date
- 2013-01-23
- Last Posted Date
- 2015-05-19
- Lead Sponsor
- Shriners Hospitals for Children
- Target Recruit Count
- 60
- Registration Number
- NCT01773096
- Locations
- 🇺🇸
Shriners Hospitals for Children- Spokane, Spokane, Washington, United States
Effects of Methylnaltrexone in Comparison to Naloxone on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time.
- Conditions
- Intestinal Obstruction
- Interventions
- Device: Colon TransitDrug: Placebo of MNTX and NLX
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2012-05-11
- Lead Sponsor
- University Medicine Greifswald
- Target Recruit Count
- 16
- Registration Number
- NCT01596764
- Locations
- 🇩🇪
Department of Clinical Pharmacology, Ernst-Moritz-Arndt-University Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany
Effects of 500 mg Immediate Release and Extended Release Methylnaltrexone on Loperamide-induced Delay of the Oro-cecal and Whole-gut Transit Time in Healthy Subjects
- Conditions
- Intestinal Obstruction
- Interventions
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- University Medicine Greifswald
- Target Recruit Count
- 15
- Registration Number
- NCT01596777
- Locations
- 🇩🇪
Department of Clinical Pharmacology, Ernst-Moritz-Arndt-University Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany
Compassionate Use Study of Methylnaltrexone
- First Posted Date
- 2011-06-08
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT01368562
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT01367509
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.